Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

ImExHS

DB:A4B
Snowflake Description

Adequate balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
A4B
DB
A$24M
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

ImExHS Limited operates as an imaging software as a service and ancillary service provider in Latin America. The last earnings update was 33 days ago. More info.


Add to Portfolio Compare Print
  • ImExHS has significant price volatility in the past 3 months.
A4B Share Price and Events
7 Day Returns
50%
DB:A4B
4.1%
DE Healthcare Services
7.3%
DE Market
1 Year Returns
-25%
DB:A4B
0.9%
DE Healthcare Services
-17.7%
DE Market
A4B Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
ImExHS (A4B) 50% -42.9% -68.4% -25% - -
DE Healthcare Services 4.1% -8.3% -18.1% 0.9% 24.9% 85.3%
DE Market 7.3% -17.9% -25.8% -17.7% -25.6% -29%
1 Year Return vs Industry and Market
  • A4B underperformed the Healthcare Services industry which returned 0.9% over the past year.
  • A4B underperformed the Market in Germany which returned -17.7% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

A4B Value

 Is ImExHS undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for ImExHS. This is due to cash flow or dividend data being unavailable. The share price is €0.006.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for ImExHS's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are ImExHS's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:A4B PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in AUD A$-0.01
ASX:IME Share Price ** ASX (2020-03-30) in AUD A$0.02
Germany Healthcare Services Industry PE Ratio Median Figure of 6 Publicly-Listed Healthcare Services Companies 11.1x
Germany Market PE Ratio Median Figure of 400 Publicly-Listed Companies 16.36x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of ImExHS.

DB:A4B PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:IME Share Price ÷ EPS (both in AUD)

= 0.02 ÷ -0.01

-3.33x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ImExHS is loss making, we can't compare its value to the DE Healthcare Services industry average.
  • ImExHS is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does ImExHS's expected growth come at a high price?
Raw Data
DB:A4B PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.33x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Healthcare Services Industry PEG Ratio Median Figure of 14 Publicly-Listed Healthcare Services Companies 2.29x
Germany Market PEG Ratio Median Figure of 254 Publicly-Listed Companies 1.2x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for ImExHS, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on ImExHS's assets?
Raw Data
DB:A4B PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in AUD A$0.01
ASX:IME Share Price * ASX (2020-03-30) in AUD A$0.02
Germany Healthcare Services Industry PB Ratio Median Figure of 7 Publicly-Listed Healthcare Services Companies 2.88x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.43x
DB:A4B PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:IME Share Price ÷ Book Value per Share (both in AUD)

= 0.02 ÷ 0.01

2.05x

* Primary Listing of ImExHS.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ImExHS is good value based on assets compared to the DE Healthcare Services industry average.
X
Value checks
We assess ImExHS's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare Services industry average (and greater than 0)? (1 check)
  5. ImExHS has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

A4B Future Performance

 How is ImExHS expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ImExHS has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
28.6%
Expected Healthcare Services industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is ImExHS expected to grow at an attractive rate?
  • Unable to compare ImExHS's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare ImExHS's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare ImExHS's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:A4B Future Growth Rates Data Sources
Data Point Source Value (per year)
Europe Healthcare Services Industry Earnings Growth Rate Market Cap Weighted Average 28.6%
Europe Healthcare Services Industry Revenue Growth Rate Market Cap Weighted Average 8.5%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.3%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:A4B Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:A4B Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2019-12-31 8 -4 -6
2019-09-30 7 -3 -6
2019-06-30 6 -3 -7
2019-03-31 6 -2 -6
2018-12-31 6 -2 -5
2018-09-30 5 -2 -3
2018-06-30 4 -1 -1
2018-03-31 4 -1 -1
2017-12-31 4 0 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if ImExHS is high growth as no earnings estimate data is available.
  • Unable to determine if ImExHS is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:A4B Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from ImExHS Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:A4B Past Financials Data
Date (Data in AUD Millions) EPS *
2019-12-31 -0.01
2019-09-30 -0.01
2019-06-30 -0.01
2019-03-31 -0.01
2018-12-31 -0.01
2018-09-30 0.00
2018-06-30
2018-03-31
2017-12-31 0.00

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if ImExHS will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine ImExHS's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. ImExHS's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  3. ImExHS's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess ImExHS's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
ImExHS has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

A4B Past Performance

  How has ImExHS performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare ImExHS's growth in the last year to its industry (Healthcare Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • ImExHS does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare ImExHS's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare ImExHS's 1-year growth to the DE Healthcare Services industry average as it is not currently profitable.
Earnings and Revenue History
ImExHS's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from ImExHS Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:A4B Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 7.73 -6.00 4.18 2.12
2019-09-30 7.15 -6.04 4.10 1.06
2019-06-30 6.43 -6.60 3.96
2019-03-31 6.10 -5.74 3.36
2018-12-31 5.78 -4.89 2.76
2018-09-30 4.86 -3.27 1.96
2018-06-30 4.07 -1.13 1.22
2018-03-31 3.81 -1.01 1.18
2017-12-31 3.55 -0.90 1.13
2016-12-31 3.05 0.09 0.95
2015-12-31 3.52 0.23 0.75

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if ImExHS has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if ImExHS has efficiently used its assets last year compared to the DE Healthcare Services industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if ImExHS improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess ImExHS's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
ImExHS has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

A4B Health

 How is ImExHS's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up ImExHS's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • ImExHS is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • ImExHS has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of ImExHS's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 7.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from ImExHS Company Filings, last reported 3 months ago.

DB:A4B Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 10.32 1.54 7.15
2019-09-30 10.32 1.54 7.15
2019-06-30 3.74 0.41 0.22
2019-03-31 3.74 0.41 0.22
2018-12-31 5.85 0.19 2.45
2018-09-30 5.85 0.19 2.45
2018-06-30 0.62 0.89 0.00
2018-03-31 0.62 0.89 0.00
2017-12-31 0.64 0.46 0.00
2016-12-31 1.22 0.00 0.02
2015-12-31 1.13 0.00 0.06
  • ImExHS's level of debt (14.9%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if ImExHS's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • ImExHS has sufficient cash runway for 1.1 years based on current free cash flow.
  • ImExHS has less than a year of cash runway if free cash flow continues to grow at historical rates of 74.4% each year.
X
Financial health checks
We assess ImExHS's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. ImExHS has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

A4B Dividends

 What is ImExHS's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from ImExHS dividends.
If you bought €2,000 of ImExHS shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate ImExHS's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate ImExHS's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:A4B Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Healthcare Services Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 1.7%
Germany Market Average Dividend Yield Market Cap Weighted Average of 323 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 1%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as ImExHS has not reported any payouts.
  • Unable to verify if ImExHS's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of ImExHS's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as ImExHS has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess ImExHS's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can ImExHS afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. ImExHS has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

A4B Management

 What is the CEO of ImExHS's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
German Arango
TENURE AS CEO 1.6 years
CEO Bio

Dr. German Arango is Chief Executive Officer and Managing Director at ImExHS Limited since August 28, 2018. Dr. Arango has been a Director of ImExHS Limited (formerly known as Omni Market Tide Ltd.) since August 28, 2018. Dr Arango is the CEO and founder of Imaging Experts and Healthcare Services S.A.S. and has over 14 years’ experience as a practising radiologist in Colombia, with a degree in Diagnostic Neuroradiology from McGill University, Montreal, Canada. Dr Arango is currently the Chairman and Staff Neuroradiologist at Mederi-Hospital Universitario Mayor, Bogota Colombia and has practised as a Neuroradiologist in various hospitals and clinics in Colombia. Dr Arango is the Associate Professor of Diagnostic Neuroradiology for the neurology and neurosurgery residency programmes for University El Rosario at Mederi – Hospital Universitario Mayor and has held various Associate Professor of Diagnostic Neuroradiology roles for Universidad Miltar de Colombia, Fundacion Universitaria de Ciencias de la Salud, Universidad Nacional de Colombia and El Bosque University during the period from 2006 to 2012.

CEO Compensation
  • Insufficient data for German to compare compensation growth.
  • Insufficient data for German to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team

German Arango

TITLE
MD, CEO & Director
TENURE
1.6 yrs

Tony Thomas

TITLE
Chief Financial Officer

Andres Vanegas

TITLE
Chief Sales Officer

Jorge Marin

TITLE
Chief Medical Officer

Peter Webse

TITLE
Company Secretary
AGE
56
TENURE
1.8 yrs
Board of Directors Tenure

Average tenure of the ImExHS board of directors in years:

1.6
Average Tenure
  • The average tenure for the ImExHS board of directors is less than 3 years, this suggests a new board.
Board of Directors

Doug Flynn

TITLE
Non-Executive Chairman
AGE
70

German Arango

TITLE
MD, CEO & Director
TENURE
1.6 yrs

Howard Digby

TITLE
Non-Executive Director
AGE
52
TENURE
2.6 yrs

Douglas Lingard

TITLE
Non-Executive Director
TENURE
1.3 yrs

Carlos Palacio

TITLE
Former Chairman of the Board
TENURE
1.7 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by ImExHS individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
04. Mar 20 Buy Douglas Lingard Individual 03. Mar 20 04. Mar 20 3,408,800 €0.02 €55,783
03. Mar 20 Buy Howard Digby Individual 03. Mar 20 03. Mar 20 689,655 €0.02 €11,840
X
Management checks
We assess ImExHS's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. ImExHS has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

A4B News

Simply Wall St News

Who Are The Largest Shareholders In Omni Market Tide Limited (FRA:A4B)?

View our latest analysis for Omni Market Tide DB:A4B Ownership_summary Apr 12th 18 Insider Ownership Insiders form another group of important ownership types as they manage the company's operations and decide the best use of capital. … With this size of ownership, retail investors can collectively play a role in major company policies that affect shareholders returns, including executive remuneration and the appointment of directors. … Private Company Ownership Potential investors in A4B should also look at another important group of investors: private companies, with a stake of 2.05%, who are primarily invested because of strategic and capital gain interests.

Simply Wall St -

Does Omni Market Tide Limited's (FRA:A4B) PE Ratio Warrant A Buy?

It compares a stock’s price per share to the stock’s earnings per share. … Formula Price-Earnings Ratio = Price per share ÷ Earnings per share P/E Calculation for A4B Price per share = A$0.01 Earnings per share = A$0.001 ∴ Price-Earnings Ratio = A$0.01 ÷ A$0.001 = 20.2x On its own, the P/E ratio doesn’t tell you much; however, it becomes extremely useful when you compare it with other similar companies. … A4B’s P/E of 20.2x is lower than its industry peers (36.4x), which implies that each dollar of A4B’s earnings is being undervalued by investors.

Simply Wall St -

Omni Market Tide Limited (FRA:A4B): Can It Deliver A Superior ROE To The Industry?

Omni Market Tide Limited (DB:A4B) generated a below-average return on equity of 4.69% in the past 12 months, while its industry returned 12.44%. … View our latest analysis for Omni Market Tide What you must know about ROE Return on Equity (ROE) weighs Omni Market Tide’s profit against the level of its shareholders’ equity. … Return on Equity = Net Profit ÷ Shareholders Equity ROE is measured against cost of equity in order to determine the efficiency of Omni Market Tide’s equity capital deployed.

Simply Wall St -

Interested In Omni Market Tide Limited (FRA:A4B)? Here's How It Performed Recently

Measuring Omni Market Tide Limited's (DB:A4B) track record of past performance is an insightful exercise for investors. … DB:A4B Income Statement Mar 12th 18 We can further examine Omni Market Tide's loss by looking at what the industry has been experiencing over the past few years. … Each year, for the past five years Omni Market Tide's top-line has increased by 27.83% on average, indicating that the company is in a high-growth period with expenses shooting ahead of revenues, leading to annual losses.

Simply Wall St -

A4B Company Info

Description

ImExHS Limited operates as an imaging software as a service and ancillary service provider in Latin America. It is involved in developing and selling Hiruko software platform that comprises radiology information system, which manages the workflow management system with a patient data and image distribution system, as well as picture archiving and communication system that allows healthcare organization to capture, store, view, and share radiology images. The company was founded in 2012 and is headquartered in Mascot, Australia.

Details
Name: ImExHS Limited
A4B
Exchange: DB
Founded: 2012
A$13,127,387
1,175,657,186
Website: http://www.imexhs.net
Address: ImExHS Limited
122 O’Riordan Street,
Mascot,
New South Wales, 2020,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX IME Ordinary Shares Australian Securities Exchange AU AUD 03. Sep 2018
DB A4B Ordinary Shares Deutsche Boerse AG DE EUR 03. Sep 2018
CHIA IME Ordinary Shares Chi-X Australia AU AUD 03. Sep 2018
Number of employees
Current staff
Staff numbers
0
ImExHS employees.
Industry
Health Care Technology
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/31 00:58
End of day share price update: 2020/03/30 00:00
Last earnings filing: 2020/02/27
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.